Effectiveness of semaglutide versus liraglutide for treating post‐metabolic and bariatric surgery weight recurrence
Obesity · 2023-05 · 31 (5) · 1280-1289
DOI: 10.1002/oby.23736 ↗At a glance
Journal article in Obesity, published online on 2023-03-30. Written by Natia Murvelashvili and 7 co-authors. Institution: Department of Internal Medicine, Division of Endocrinology, UT Southwestern Medical Center, Dallas, Texas, USA. Major MEDLINE topics: Bariatric Surgery, Liraglutide, Obesity, Morbid, Weight Gain. Cited 87 times so far (Crossref); 25 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIDDK NIH HHS, NIMHD NIH HHS.
Abstract (original language)
Objective
The aim of this study was to compare the effectiveness of semaglutide versus liraglutide for treating post‐metabolic and bariatric surgery (MBS) weight recurrence.
Methods
A retrospective analysis of 207 adults with post‐MBS weight recurrence treated with semaglutide 1.0 mg weekly ( n = 115) or liraglutide 3.0 mg daily ( n = 92) at an academic center from January 1, 2015, through April 1, 2021, was conducted. The primary end point was percentage body weight change at 12 months of treatment with regimens containing semaglutide or liraglutide.
Results
The mean sample age was 55.2 years; mean BMI was 40.4 kg/m 2 ; 89.9% were female; and 50% completed sleeve gastrectomy, 29% completed Roux‐en‐Y gastric bypass, and 21% completed adjustable gastric banding. Least‐squares mean weight change at 12 months was −12.92% versus −8.77% in the semaglutide and liraglutide groups, respectively ( p < 0.001). The adjusted odds ratios were 2.34 (95% CI: 1.28‐4.29) for ≥10% weight loss and 2.55 (95% CI: 1.22‐5.36) for ≥15% weight loss over 12 months in the semaglutide group versus liraglutide group, respectively. Weight‐loss efficacy of semaglutide (vs. liraglutide) did not differ by subgroups explored, including age, sex, and MBS procedure.
Conclusions
These results show that treatment regimens including semaglutide 1.0 mg weekly lead to superior weight loss compared with liraglutide 3.0 mg daily for treating post‐MBS weight recurrence, regardless of procedure type or the magnitude of weight recurrence.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Internal Medicine, Division of Endocrinology, UT Southwestern Medical Center, Dallas, Texas, USA.
- University of Texas Health Science Center, School of Public Health, Dallas, Texas, USA.
- Center for Pediatric Population Health, UT Health School of Public Health, Dallas, Texas, USA.
- Peter O'Donnell Jr. School of Public Health, UT Southwestern Medical Center, Dallas, Texas, USA.
- Department of Pediatrics, John P. and Kathrine G. McGovern School of Medicine at UTHealth, Houston, Texas, USA.
ORCID profiles: Luyu Xie, Ildiko Lingvay, Sarah E Messiah, Jaime P Almandoz
Funding
- NIDDK NIH HHS
- NIMHD NIH HHS
Cite
APA
Murvelashvili, N., Xie, L., Schellinger, J. N., Mathew, M. S., Marroquin, E. M., Lingvay, I., Messiah, S. E., & Almandoz, J. P. (2023). Effectiveness of semaglutide versus liraglutide for treating post‐metabolic and bariatric surgery weight recurrence. Obesity, 31(5), 1280-1289. https://doi.org/10.1002/oby.23736
Vancouver
Murvelashvili N, Xie L, Schellinger JN, Mathew MS, Marroquin EM, Lingvay I, et al. Effectiveness of semaglutide versus liraglutide for treating post‐metabolic and bariatric surgery weight recurrence. Obesity. 2023;31(5):1280-1289. doi:10.1002/oby.23736
BibTeX
@article{Murvelashvili2023,
author = {Murvelashvili, Natia and Xie, Luyu and Schellinger, Jeffrey N and Mathew, M Sunil and Marroquin, Elisa Morales and Lingvay, Ildiko and Messiah, Sarah E and Almandoz, Jaime P},
title = {Effectiveness of semaglutide versus liraglutide for treating post‐metabolic and bariatric surgery weight recurrence},
journal = {Obesity},
year = {2023},
volume = {31},
number = {5},
pages = {1280--1289},
doi = {10.1002/oby.23736}
}
EUVIMED